8/4/2019 Teaching Project Gp Year 4 New
1/23
Breast cancer,brief recap
Investigations
andManagement-
and their role inBreast cancer
CASE STUDYInteractivemanagement
discussion
Quiz
8/4/2019 Teaching Project Gp Year 4 New
2/23
BRIEF RECAP!
8/4/2019 Teaching Project Gp Year 4 New
3/23
Pathology Epidemiology
Risk Factors Presentation
BreastCancer
8/4/2019 Teaching Project Gp Year 4 New
4/23
Most breast cancers areeither:
DUCTAL orLOBULAR
Carcinoma can be invasiveor in situ.
8/4/2019 Teaching Project Gp Year 4 New
5/23
Paget's disease of breast is an infiltratingcarcinoma of the nipple epithelium andrepresents about 1% of all breast cancers.
Inflammatory carcinoma occurs in under 3%all cases with a rapidly growing, sometimespainful mass enlarging the breast and causingthe overlying skin to become red and warm.There may be diffuse infiltration of tumour.
http://www.patient.co.uk/DisplayConcepts.asp?WordId=PAGET%20S%20DISEASE%20OF%20BREAST&MaxResults=50http://www.patient.co.uk/DisplayConcepts.asp?WordId=PAGET%20S%20DISEASE%20OF%20BREAST&MaxResults=508/4/2019 Teaching Project Gp Year 4 New
6/23
It represents almost 1 in 3 of all malignancies in women.
75% of new cases are aged over 50 years.
The death rate from breast cancer is falling. This is probably due to better treatment butmammography may also be detecting cases earlier.
In less than 1% of cases there is simultaneous bilateral breast cancer.
Breast cancer can occur in men, usually in men aged over 50 years.
8/4/2019 Teaching Project Gp Year 4 New
7/23
8/4/2019 Teaching Project Gp Year 4 New
8/23
Breast lump
Breast pain
Change in the sizeor shape of the
breast
Ulceration of the
breast skin
ADVANCED
Occasionally-Fungating mass
Bone pain,
Pathological #
Jaundice
Dimpling of the
breast skin
Involution orinversion of thenipple
Nipple dischargeor bleeding
Axillary
lymphadenopathy
8/4/2019 Teaching Project Gp Year 4 New
9/23
8/4/2019 Teaching Project Gp Year 4 New
10/23
?
??
?
8/4/2019 Teaching Project Gp Year 4 New
11/23
Triple assessment
Clinical examination
A radiological assessment mammography or ultrasound (usually
combined)
A pathological assessment cytology
and/or core biopsy
sensitivity
andspecificity>90%
8/4/2019 Teaching Project Gp Year 4 New
12/23
TX means that the tumour size cannot be assessed
T1 - The tumour is no more than 2 centimetres (cm) acrossT2 - The tumour is more than 2 centimetres, but no more than 5centimetres acrossT3 - The tumour is bigger than 5 centimetres across
T4 Any size tumour involving chest wall or skin ( imflammatory breastcancer also)
The N stages (nodes)N0 - No cancer cells found in any nearby nodesN1 MOBILE axillary lymphadenopathy ie not stuck to surrounding
tissuesN2- Fixed axillary lymph nodes and/or mammary lymph node involvementN3
8/4/2019 Teaching Project Gp Year 4 New
13/23
SurgicalTreatment
Followup
Pathologicalassessment andstaging to directadjuvant therapy
ADJUVANT
THERAPY
Disease that can be fully removed by surgery T1-3 N0-1
8/4/2019 Teaching Project Gp Year 4 New
14/23
All patients require complete removal of the 1 tumour:WLEMASTECTOMY
WLE= removal of tumour mass with limited margin of uninvolvedsurrounding tissue (~0.5-1cm). This is now the most commonlyperformed procedure for early breast cancer.
MASTECTOMY = preferred if e.g. patient would prefer, inflammatory
carcinoma, large tumour in small breast, multifocal primaries etc.
Breast reconstruction can be offered either at time of primary surgeryor later- TRAM flap, lat dorsi flap and implants.
8/4/2019 Teaching Project Gp Year 4 New
15/23
AXILLARY CLEARANCE/DISSECTION-Complete staging of axillaProvides regional control of disease and no need for RTDisadvantages outweigh benefits in the lower risk patientsSIDE EFFECTS- painful arm, lymphoedema, sensory loss, debilitatingshoulder stiffness
AXILLARY SAMPLING- At least 4 nodes If surgeon is suspicious, perhaps will remove morePatient with +ve sample may then have axillary clearance, or morecommonly RT to the axillaLess morbidity in node negative patients than with a full clearance
SENTINEL NODE BIOSPY-Patients with unidentified lymphadenopathyIdentification and removal of first draining lymph nodeInjection of blue dye and radio-labelled colloidAny stained node/s removed
8/4/2019 Teaching Project Gp Year 4 New
16/23
Usually after surgery, unless patient is having
chemotherapy.Some women may not need at all e.g. Mastectomy withvery low risk recurrence.Recommended for all women with breast conserving
surgery. 5 WEEK course, treatment to the whole breast
AXILLARY RADIOTHERAPY= SAMPLING maybeCLEARANCE NO
Can offer to the SCF if patient lymph node +ve more than
4 nodes
8/4/2019 Teaching Project Gp Year 4 New
17/23
WHO NEEDS ADJUVANT THERAPY??Women with NODE +VE BREAST CANCER.
Take into account tumour grade, node status etcDecision making- clinical judgementNPI NOTTINGHAM PROGNOSTIC INDEX - sum of the tumour size(cm x 0.2) + lymph node stage + histological gradeGood prognosis= less than 3.4Poor= more than 5.4
CHEMOTHERAPYBIOLOGICAL THERAPYENDOCRINE THERAPY
8/4/2019 Teaching Project Gp Year 4 New
18/23
Greater benefit to younger patients
all women under the age of 70yrs should be considered foradjuvant chemo.
6 month cycle using a combination of drugs seems to be thepreferred.
E/CMF
Can be given as a Neo-adjuvant
8/4/2019 Teaching Project Gp Year 4 New
19/23
IE HORMONAL AGENTS
Only works if ER +ve!!
may be used as the only treatment if comorbidities , ie over 70sUp to 5 yr treatment durationTamoxifenstops oestrogen from binding to oestrogen-receptor-positive cancer cells.
Aromatase inhibitorsPost menopausal oestrogen suppression
Ovarian ablation or suppressionGoserelin- a lutenising hormone-releasing hormone agonist (LHRHa).Offer to women who refuse chemotherapy. (Option of choice= chemo +
tamoxifen)
8/4/2019 Teaching Project Gp Year 4 New
20/23
HER-2 +ve breast cancerHERCEPTIN (trastuzamab)Inpatient3 week intervals for 1 yrASSESS CARDIAC FUNTION BEFOREHAND!! Do not give if
less than LVEF less than 55%3 monthly echoSTOP if LVF drops by 10% and below 50
8/4/2019 Teaching Project Gp Year 4 New
21/23
IE broadly speaking, T4, N2
Median survival exceeds 2 years
Staging investigations should include:
CXR, isotope bone scan
Liver US or CT scan
8/4/2019 Teaching Project Gp Year 4 New
22/23
15-20% present with metastatic disease
PALLIATION IS THE AIM
ER +VE longer survivalCommon sites= lung, pleura, bone, brain
CHEMOTHERAPY- MODERATE RESPONSER adiotherapy- Bone pain, soft tissue disease, and certain metastasesBISPHOSPHONATES
8/4/2019 Teaching Project Gp Year 4 New
23/23